Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo
Mary E. Rinella1; Manal F. Abdelmalek2; Elisabetta Bugianesi3; Anna M.G. Calí4; Laurent Castera5,6; Kristiane A. Engebretsen4; Jacob George7; Wah Kheong Chan8; Niels Krarup4; Michelle T. Long4; Philip Newsome9,10; Cláudia P. Oliveira11; Georgios Papatheodoridis12; Ahsan Shoeb4; Salvatore Petta13; Michael Roden14,15,16; Arun J. Sanyal17; Yusuf Yilmaz18; Vlad Ratziu19; on behalf of the ESSENCE Study Group
MATERIALS AVAILABLE
Coming soon
Thursday, 08 May 2025
12:45 - 13:45
CEST
Add to calendar
Symposium
Updates on the essence of MASH
Elizabeth Powell; Philip Newsome; Faiez Zannad; Steven Kahn
MATERIALS AVAILABLE
Teaser Video
Saturday, 10 May 2025
11:45 - 12:45
CEST
Add to calendar
Symposium
Personalised management of MASH
Jörn M. Schattenberg; Alina M. Allen; Jean-Francois Dufour